DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
Barchart on MSN
DexCom Stock: Is Wall Street Bullish or Bearish?
Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.
Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on ...
Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...
Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen ...
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...
Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...
If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...
StockStory.org on MSN
Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
DexCom reported revenues of $1.21 billion, up 21.6% year on year. This print exceeded analysts’ expectations by 2.5%. Overall, it was a strong quarter for the company with a solid beat of analysts’ ...
President and COO Jacob Steven Leach, has recently purchased shares of the company, according to a Form 4 filing with the Securities and Exchange Commission. On November 10, 2025, Leach acquired a ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results